Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free PSTV Stock Alerts

Plus Therapeutics (PSTV) Financials

Plus Therapeutics logo
$3.83 -0.03 (-0.78%)
As of 08/7/2026
Compare
Annual Income Statements for Plus Therapeutics

Annual Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -19 -22 -27 -15 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -8.88 -3.28 -8.24 -13 -20 -13 -13 -22
Total Pre-Tax Income 		-19 -22 -23 -8.41 -5.46 -8.24 -13 -20 -13 -13 -22
Total Operating Income		 -15 -20 -21 -8.76 -3.66 -9.58 -12 -20 -13 -15 -15
Total Gross Profit		 1.65 1.94 0.15 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Total Revenue		 4.84 4.66 2.69 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Operating Revenue		 4.84 4.66 2.69 - - - 0.00 0.22 4.91 5.82 5.21
Total Cost of Revenue		 3.19 2.72 2.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 22 21 8.76 3.66 9.58 12 20 18 21 21
Selling, General & Admin Expense		 9.77 8.56 7.59 5.58 5.29 6.41 6.85 10 8.54 9.94 12
Research & Development Expense		 12 9.47 13 5.52 5.37 3.48 5.57 9.70 9.69 11 8.38
Total Other Income / (Expense), net		 -3.46 -2.34 -2.00 0.35 -1.80 1.34 -0.91 -0.56 0.01 1.72 -7.09
Interest Expense		 3.64 2.59 2.05 1.92 1.86 1.11 0.93 0.71 0.40 0.18 0.55
Interest & Investment Income		 0.01 0.02 0.03 0.04 0.06 0.05 0.02 0.15 0.40 0.27 0.12
Other Income / (Expense), net		 0.17 0.23 0.01 2.23 - 2.40 0.01 - 0.00 1.62 -6.66
Basic Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($1.95) ($0.29)
Weighted Average Basic Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 6.64M 77.80M
Diluted Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($2.34) ($0.29)
Weighted Average Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 7.70M 77.80M
Weighted Average Basic & Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 35.11M 4.28M 17.00M 171.55M

Quarterly Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Consolidated Net Income / (Loss)		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Net Income / (Loss) Continuing Operations		 -3.19 -3.85 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Total Pre-Tax Income 		-3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Total Operating Income		 -3.25 -3.86 -3.30 -3.70 -3.80 -3.90 -3.54 -1.54 -4.48 -5.74 -7.12
Total Gross Profit		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Total Revenue		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Operating Revenue		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.49 5.17 4.98 4.98 5.26 5.31 4.60 2.93 5.88 7.11 8.15
Selling, General & Admin Expense		 2.00 2.38 2.21 2.20 2.40 3.13 2.84 1.68 3.44 4.17 5.28
Research & Development Expense		 2.49 2.79 2.76 2.77 2.86 2.19 1.76 1.25 2.44 2.94 2.87
Total Other Income / (Expense), net		 0.03 0.05 0.04 0.76 0.93 -0.00 -14 6.69 0.06 0.03 0.17
Interest Expense		 0.09 0.06 0.03 0.03 0.06 0.06 0.55 0.00 0.00 - 0.02
Interest & Investment Income		 0.12 0.11 0.07 0.07 0.08 0.05 0.00 0.03 0.06 0.03 0.19
Other Income / (Expense), net		 0.00 - 0.00 0.72 0.91 - -13 6.66 0.00 - 0.00
Basic Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.45) ($0.37) ($0.59) ($29.86) $0.02 ($0.04) $0.92 ($1.05)
Weighted Average Basic Shares Outstanding		 3.23M 3.14M 4.32M 6.50M 7.86M 6.64M 582.67K 48.39M 107.43M 77.80M 6.65M
Diluted Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.71) ($0.37) ($0.59) ($29.86) ($0.01) ($0.04) $0.95 ($1.05)
Weighted Average Diluted Shares Outstanding		 3.23M 3.14M 4.32M 10.74M 7.86M 7.70M 582.67K 209.15M 107.43M 77.80M 6.65M
Weighted Average Basic & Diluted Shares Outstanding		 4.52M 4.28M - 5.90M 5.90M 17.00M 32.72M 99.26M 137.43M 171.55M 6.88M

Annual Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.28 -1.78 -2.69 -4.92 12 -9.25 10 -0.28 -9.57 -8.48 8.68
Net Cash From Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Cash From Continuing Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Depreciation Expense		 1.09 1.18 2.15 2.00 0.90 0.37 0.40 0.62 0.63 0.87 0.45
Amortization Expense		 0.98 0.95 0.71 0.58 0.55 0.58 0.57 0.39 0.19 -0.11 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -5.10 1.40 2.74 -0.89 4.47 -1.26 0.92 0.70 0.76 -2.13 7.47
Changes in Operating Assets and Liabilities, net		 1.30 -1.09 -1.04 -1.03 -0.94 0.12 1.24 5.60 -1.12 3.79 -6.29
Net Cash From Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Net Cash From Continuing Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Purchase of Property, Plant & Equipment		 -0.61 -0.07 -1.50 -0.13 -0.07 -0.09 -0.14 -0.51 -0.16 -0.15 -0.07
Acquisitions		 -0.01 - - - 0.00 -0.40 - - 0.00 -0.55 0.00
Purchase of Investments		 - - - - - - - - 0.00 -16 -9.35
Sale of Property, Plant & Equipment		 0.01 0.13 0.11 - - 0.00 0.06 - - 0.00 0.03
Sale and/or Maturity of Investments		 - - - - - - - - 0.00 12 8.54
Other Investing Activities, net		 - 0.00 - - - - 0.00 -0.25 0.00 0.00 0.00
Net Cash From Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Net Cash From Continuing Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Repayment of Debt		 -27 0.00 -4.72 0.00 -3.69 -5.31 -0.27 -1.61 -1.61 -4.00 -9.25
Repurchase of Common Equity		 -2.37 -2.08 -2.08 - 0.00 - 0.00 -0.77 -0.47 -0.37 -0.23
Issuance of Debt		 18 - - - - - - - 0.00 3.29 4.49
Issuance of Common Equity		 29 21 24 0.00 16 4.01 19 16 0.00 0.00 23
Other Financing Activities, net		 3.37 -1.77 0.00 7.17 0.36 0.98 2.01 - 5.53 7.27 13
Cash Interest Paid		 1.99 1.62 1.36 1.33 1.19 0.57 0.39 0.33 0.22 0.03 0.00

Quarterly Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.11 -2.45 -5.65 2.01 -3.69 -1.15 9.79 -7.63 11 -4.53 -5.74
Net Cash From Operating Activities		 -2.40 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24
Net Cash From Continuing Operating Activities		 -2.40 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24
Net Income / (Loss) Continuing Operations		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Consolidated Net Income / (Loss)		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Depreciation Expense		 0.16 0.15 0.16 0.17 0.20 0.35 0.15 0.08 0.08 0.15 0.10
Amortization Expense		 0.07 -0.06 0.02 -0.02 -0.05 -0.06 0.04 -0.02 0.00 0.01 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -0.59 0.35 0.18 -0.97 -0.80 -0.54 13 -7.52 0.99 0.91 0.01
Changes in Operating Assets and Liabilities, net		 1.18 1.49 -1.60 2.61 -0.16 2.94 -2.01 -3.48 0.81 -1.61 0.61
Net Cash From Investing Activities		 -0.01 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53
Net Cash From Continuing Investing Activities		 -0.01 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53
Purchase of Property, Plant & Equipment		 -0.01 -0.04 -0.04 -0.08 -0.01 -0.01 -0.00 -0.01 -0.03 -0.03 -0.82
Acquisitions		 - - - - - - 0.00 - -0.01 0.01 0.00
Purchase of Investments		 - - - - -3.65 -8.45 0.00 - -3.31 1.72 -9.70
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.03 - - - 0.00
Sale and/or Maturity of Investments		 - - -0.32 0.32 3.65 8.52 3.53 3.13 4.64 -2.77 1.99
Net Cash From Financing Activities		 2.52 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04
Net Cash From Continuing Financing Activities		 2.52 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04
Repayment of Debt		 -0.40 -0.40 -0.40 -3.59 - - -7.00 - -2.25 - -1.10
Repurchase of Common Equity		 - -0.47 -0.37 -0.05 0.05 - 0.00 -0.22 -0.01 - -1.36
Issuance of Debt		 - - 0.00 3.29 - - 3.74 - - 0.75 1.00
Issuance of Common Equity		 -2.26 - 0.00 - - - 0.00 -12 17 3.00 0.00
Other Financing Activities, net		 - 0.35 0.00 7.31 -0.05 - 16 15 -2.25 -0.95 10
Cash Interest Paid		 0.05 0.04 0.02 0.01 - - 0.54 0.54 - -0.54 0.00

Annual Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 38 35 32 24 23 12 22 24 11 6.63 16
Total Current Assets		 21 19 15 9.65 20 9.18 20 22 9.83 5.26 15
Cash & Equivalents		 14 13 9.55 5.26 18 8.35 18 18 8.55 0.08 4.26
Restricted Cash		 0.00 0.35 0.68 0.04 0.04 - - - - 0.00 4.50
Short-Term Investments		 - - - - - - - - 0.00 3.53 4.36
Other Current Assets		 1.56 0.87 1.31 0.79 0.96 0.83 1.32 3.70 1.28 1.65 2.06
Plant, Property, & Equipment, net		 1.63 1.16 3.05 2.30 2.18 1.82 1.48 1.32 0.91 0.45 0.26
Total Noncurrent Assets		 15 15 14 12 1.23 1.11 0.78 0.73 0.65 0.93 0.90
Goodwill		 3.92 3.92 3.92 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 9.03 8.45 7.21 - 0.00 0.09 0.05 0.09 0.04 0.47 0.33
Other Noncurrent Operating Assets		 1.52 2.34 2.57 0.04 0.85 0.65 0.36 0.26 0.23 0.09 0.19
Total Liabilities & Shareholders' Equity		 38 35 32 24 23 12 22 24 11 6.63 16
Total Liabilities		 25 24 19 19 22 9.07 11 17 13 16 12
Total Current Liabilities		 8.44 13 18 18 14 8.54 5.87 12 11 16 12
Short-Term Debt		 0.00 6.63 14 14 11 6.34 1.61 1.61 3.98 3.29 0.75
Accounts Payable		 6.69 5.87 4.79 2.78 3.28 2.08 4.15 10 6.63 11 5.92
Current Deferred Revenue		 - - - - - - - - 0.00 0.93 0.93
Other Current Liabilities		 1.75 - - - 0.15 0.12 0.11 0.11 0.12 0.04 4.72
Total Noncurrent Liabilities		 17 11 0.20 1.21 7.58 0.54 5.28 5.57 2.01 0.03 0.02
Other Noncurrent Operating Liabilities		 - - - 0.96 7.58 0.54 0.27 1.78 2.01 0.03 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Total Preferred & Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Common Stock		 368 389 413 418 426 437 458 474 479 485 520
Retained Earnings		 -357 -379 -402 -414 -425 -434 -447 -467 -481 -493 -516
Treasury Stock		 - - - - - - - 0.00 -0.13 -0.50 -0.50

Quarterly Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 13 5.62 11 6.98 12 10 19 20
Total Current Assets		 12 4.21 9.38 5.36 11 9.21 18 18
Cash & Equivalents		 11 2.90 4.91 1.22 9.87 2.23 13 3.02
Restricted Cash		 - - - - - - - 0.00
Short-Term Investments		 - 0.32 3.52 3.57 0.00 4.65 3.31 12
Other Current Assets		 0.58 0.99 0.95 0.58 1.00 2.34 0.99 2.91
Plant, Property, & Equipment, net		 1.01 0.80 0.73 0.59 0.32 0.29 0.27 1.01
Total Noncurrent Assets		 0.69 0.61 1.10 1.02 0.86 0.85 0.81 0.88
Goodwill		 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 0.05 0.03 0.56 0.51 0.44 0.40 0.37 0.30
Other Noncurrent Operating Assets		 0.26 0.20 0.17 0.14 0.06 0.07 0.07 0.20
Total Liabilities & Shareholders' Equity		 13 5.62 11 6.98 12 10 19 20
Total Liabilities		 11 10 19 12 36 7.32 14 7.96
Total Current Liabilities		 11 10 19 12 11 7.32 14 7.96
Short-Term Debt		 4.35 3.59 3.29 3.29 0.00 0.00 0.00 0.67
Accounts Payable		 6.07 6.45 6.95 7.91 9.22 6.36 12 6.16
Current Deferred Revenue		 - 0.25 2.30 0.84 1.30 0.93 1.97 0.93
Other Current Liabilities		 0.12 0.12 6.25 0.07 0.04 0.03 0.02 0.20
Total Noncurrent Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Total Preferred & Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Common Stock		 479 479 480 485 488 509 516 535
Retained Earnings		 -477 -484 -487 -490 -511 -506 -510 -523
Treasury Stock		 - -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50

Annual Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 158,458,195.00 20,500,553.00 35,119,410.00 13,201,410.00 3,770,588.00 4,779,584.00 15,360,025.00 33,601,373.00 4,522,656.00 5,896,333.00 137,429,055.00
DEI Adjusted Shares Outstanding		 1,409.00 2,733.00 4,683.00 17,602.00 251,373.00 318,639.00 1,024,002.00 2,240,092.00 4,522,656.00 235,853.00 5,497,162.00
DEI Earnings Per Adjusted Shares Outstanding		 -13,772.18 -8,066.59 -5,693.57 -859.05 -45.51 -25.86 -13.08 -9.05 -2.94 -55.03 -4.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.32% -3.76% -42.25% -100.00% 0.00% 0.00% 0.00% 0.00% 2,093.30% 18.54% -10.49%
EBITDA Growth		 57.93% -32.93% -2.74% 77.84% 43.98% -181.95% -84.81% -62.35% 33.15% 1.54% -74.79%
EBIT Growth		 54.20% -28.84% -6.15% 68.41% 43.99% -96.45% -73.80% -57.87% 32.42% 1.87% -67.95%
NOPAT Growth		 52.87% -28.92% -4.96% 57.64% 58.26% -162.07% -30.34% -57.80% 32.42% -10.31% -4.10%
Net Income Growth		 49.84% -17.62% -2.90% 44.31% 13.83% 24.30% -62.59% -51.32% 34.32% 2.54% -72.49%
EPS Growth		 49.84% 38.16% -2.90% 44.31% 90.49% 77.51% 40.32% -51.32% 63.39% 44.81% 87.61%
Operating Cash Flow Growth		 32.52% 4.57% 7.19% 33.94% 50.68% -42.80% -21.89% -26.19% 0.93% 17.87% -96.84%
Free Cash Flow Firm Growth		 -45.43% 24.10% 0.94% 167.43% -72.10% -559.18% 48.30% -25.02% -14.30% 28.21% -66.97%
Invested Capital Growth		 200.19% 10.66% 4.37% -99.75% -13,202.44% 118.99% -193.24% -560.46% 5.65% -56.31% 9.66%
Revenue Q/Q Growth		 -15.88% -1.90% -23.02% -100.00% 100.00% 0.00% 0.00% 206.85% 30.98% 1.73% -0.86%
EBITDA Q/Q Growth		 17.11% -14.46% 2.55% 49.00% -1,105.00% 15.60% -4.58% -10.27% 11.57% 12.59% -9.38%
EBIT Q/Q Growth		 14.72% -12.87% 2.06% 36.28% -122.18% 14.49% -4.50% -9.03% 11.40% 10.79% -9.16%
NOPAT Q/Q Growth		 12.77% -8.30% -0.20% 27.32% -105.22% -14.08% -4.55% -9.03% 11.40% -0.29% -13.69%
Net Income Q/Q Growth		 13.77% -10.83% 2.71% 13.96% 22.27% -118.59% -4.43% -8.01% 12.19% -0.72% -8.80%
EPS Q/Q Growth		 13.77% -31.96% 2.71% 13.96% 53.06% -100.00% -18.09% -8.01% 9.79% -42.68% -52.63%
Operating Cash Flow Q/Q Growth		 2.08% 1.81% -0.35% 12.66% 37.37% -102.06% 5.51% 2.92% 2.67% 5.97% -32.08%
Free Cash Flow Firm Q/Q Growth		 -37,883.43% 42.07% -2.74% 281.50% -84.00% -2.08% 8.65% 8.77% -0.47% 8.84% -155.46%
Invested Capital Q/Q Growth		 574.86% -0.51% 1.83% -99.69% 7.01% -13.27% -518.94% -99.65% -46.83% -38.88% 27.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 34.15% 41.69% 5.43% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -269.57% -372.36% -662.40% 0.00% 0.00% 0.00% 0.00% -8,350.00% -254.49% -211.38% -412.78%
Operating Margin		 -315.96% -423.24% -769.17% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -252.32% -293.46%
EBIT Margin		 -312.40% -418.23% -768.69% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -224.45% -421.14%
Profit (Net Income) Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.34% -271.04% -222.84% -429.43%
Tax Burden Percent		 100.00% 100.00% 100.00% 150.26% 199.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 124.02% 113.21% 109.75% 128.78% 149.22% 114.71% 107.31% 102.86% 99.96% 99.28% 101.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -113.06% -92.23% -90.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -242.53% -337.82% -292.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -463.33% -97.89% -98.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Cash Return on Invested Capital (CROIC)		 -213.10% -102.35% -94.45% 124.39% 0.00% -1,284.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -39.56% -53.86% -62.42% 0.00% 0.00% 0.00% 0.00% -85.99% -75.57% -145.08% -191.25%
Return on Assets (ROA)		 -49.06% -60.98% -68.51% 0.00% 0.00% 0.00% 0.00% -88.44% -75.54% -144.03% -195.02%
Return on Common Equity (ROCE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Return on Equity Simple (ROE_SIMPLE)		 -153.56% -200.67% -174.51% -241.80% -938.53% -271.89% -123.65% -314.58% 987.83% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.74 -14 -9.32 -10 -11
NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Net Nonoperating Expense Percent (NNEP)		 129.48% 245.59% 202.02% -728.36% -142.15% -35.87% -67.47% -52.84% -46.13% -110.04% -184.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -354.82% 181.84% -225.63%
Cost of Revenue to Revenue		 65.85% 58.31% 94.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 201.84% 183.91% 282.41% 0.00% 0.00% 0.00% 0.00% 4,570.54% 173.91% 170.66% 232.73%
R&D to Revenue		 251.74% 203.46% 496.99% 0.00% 0.00% 0.00% 0.00% 4,329.46% 197.23% 181.66% 160.73%
Operating Expenses to Revenue		 350.10% 464.93% 774.60% 0.00% 0.00% 0.00% 0.00% 8,900.00% 371.14% 352.32% 393.46%
Earnings before Interest and Taxes (EBIT)		 -15 -19 -21 -6.53 -3.66 -7.18 -12 -20 -13 -13 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -17 -18 -3.95 -2.21 -6.23 -12 -19 -13 -12 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.40 2.82 0.81 0.73 7.80 3.19 1.49 1.65 0.00 0.00 17.62
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.66 0.79 11.48 3.75 1.55 1.78 0.00 0.00 21.39
Price to Revenue (P/Rev)		 6.06 6.65 3.94 0.00 0.00 0.00 0.00 47.55 1.61 1.16 13.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.23 2.27 0.85 310.47 0.00 7.49 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6.54 7.66 5.20 0.00 0.00 0.00 0.00 0.00 0.68 1.11 11.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 1.25 0.88 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.37 1.61 1.05 2.72 9.53 2.09 0.61 0.84 -2.95 -0.37 0.19
Long-Term Debt to Equity		 1.37 1.00 0.00 0.00 0.00 0.00 0.46 0.59 0.00 0.00 0.00
Financial Leverage		 1.91 0.29 0.34 -0.10 -1.83 -2.04 -1.00 -1.42 -3.39 0.48 2.56
Leverage Ratio		 11.75 3.12 2.76 3.05 7.40 8.43 2.46 2.65 6.92 -1.75 -4.64
Compound Leverage Factor		 14.57 3.53 3.03 3.93 11.04 9.67 2.64 2.73 6.91 -1.74 -4.73
Debt to Total Capital		 57.75% 61.62% 51.17% 73.10% 90.51% 67.64% 37.90% 45.56% 151.29% -58.19% 15.80%
Short-Term Debt to Total Capital		 0.00% 23.16% 51.17% 73.10% 90.51% 67.64% 9.22% 13.58% 151.29% -58.19% 15.80%
Long-Term Debt to Total Capital		 57.75% 38.46% 0.00% 0.00% 0.00% 0.00% 28.68% 31.98% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 42.25% 38.38% 48.83% 26.90% 9.49% 32.36% 62.10% 54.44% -51.29% 158.19% 84.20%
Debt to EBITDA		 -1.28 -1.02 -0.76 -3.60 -5.00 -1.02 -0.57 -0.29 -0.32 -0.27 -0.03
Net Debt to EBITDA		 -0.18 -0.27 -0.19 -2.26 2.95 0.32 1.02 0.68 0.37 0.03 0.57
Long-Term Debt to EBITDA		 -1.28 -0.63 0.00 0.00 0.00 0.00 -0.43 -0.20 0.00 0.00 0.00
Debt to NOPAT		 -1.56 -1.28 -0.94 -2.32 -4.32 -0.94 -0.76 -0.39 -0.43 -0.32 -0.07
Net Debt to NOPAT		 -0.22 -0.34 -0.23 -1.45 2.55 0.30 1.35 0.92 0.49 0.03 1.15
Long-Term Debt to NOPAT		 -1.56 -0.80 0.00 0.00 0.00 0.00 -0.57 -0.27 0.00 0.00 0.00
Altman Z-Score		 -13.36 -16.05 -19.66 -25.35 -25.63 -51.39 -28.71 -29.25 -62.22 -111.38 -44.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.52 1.50 0.81 0.55 1.37 1.07 3.36 1.84 0.92 0.34 1.23
Quick Ratio		 1.82 1.10 0.53 0.31 1.29 0.98 3.13 1.53 0.80 0.23 0.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -15 -15 10 2.85 -13 -6.77 -8.47 -9.68 -6.95 -12
Operating Cash Flow to CapEx		 -3,411.33% 0.00% -1,310.77% -9,003.76% -8,814.93% -9,068.82% -12,536.59% -2,548.53% -8,031.88% -7,228.77% -56,148.65%
Free Cash Flow to Firm to Interest Expense		 -5.54 -5.91 -7.40 5.32 1.54 -11.83 -7.27 -11.91 -24.51 -38.82 -21.17
Operating Cash Flow to Interest Expense		 -5.62 -7.54 -8.85 -6.23 -3.18 -7.62 -11.03 -18.24 -32.53 -58.96 -37.91
Operating Cash Flow Less CapEx to Interest Expense		 -5.79 -7.51 -9.52 -6.30 -3.22 -7.70 -11.12 -18.96 -32.94 -59.78 -37.98
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.08 0.00 0.00 0.00 0.00 0.01 0.28 0.65 0.45
Accounts Receivable Turnover		 4.22 4.06 3.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.70 0.68 0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.01 3.34 1.28 0.00 0.00 0.00 0.00 0.16 4.41 8.60 14.79
Accounts Payable Turnover		 0.52 0.43 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 86.57 89.92 94.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 522.81 539.30 495.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 700.73 844.21 765.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -91.35 -214.99 -175.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 14 16 16 0.04 -5.37 1.02 -0.95 -6.28 -5.93 -9.26 -8.37
Invested Capital Turnover		 0.51 0.31 0.17 0.00 0.00 0.00 0.00 -0.06 -0.80 -0.77 -0.59
Increase / (Decrease) in Invested Capital		 9.47 1.51 0.69 -16 -5.41 6.39 -1.97 -5.33 0.36 -3.34 0.90
Enterprise Value (EV)		 32 36 14 13 2.52 7.64 4.34 -2.07 3.34 6.47 58
Market Capitalization		 29 31 11 3.83 9.05 9.65 16 11 7.92 6.78 70
Book Value per Share		 $0.08 $0.54 $0.37 $0.40 $0.31 $0.63 $0.71 $0.19 ($0.30) ($1.52) $0.03
Tangible Book Value per Share		 $0.00 ($0.07) $0.05 $0.37 $0.21 $0.54 $0.68 $0.18 ($0.39) ($1.66) $0.02
Total Capital		 29 29 27 19 12 9.37 17 12 2.63 -5.66 4.75
Total Debt		 17 18 14 14 11 6.34 6.61 5.39 3.98 3.29 0.75
Total Long-Term Debt		 17 11 0.00 0.00 0.00 0.00 5.01 3.79 0.00 0.00 0.00
Net Debt		 2.34 4.73 3.40 8.90 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Capital Expenditures (CapEx)		 0.60 -0.06 1.38 0.13 0.07 0.09 0.08 0.51 0.16 0.15 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.53 -0.04 -0.15 0.99 -1.19 -1.38 -2.94 -6.55 -5.47 -11 -9.51
Debt-free Net Working Capital (DFNWC)		 13 13 10 6.29 16 6.97 15 12 3.08 -7.00 3.61
Net Working Capital (NWC)		 13 6.25 -3.55 -7.91 5.34 0.64 14 9.97 -0.89 -10 2.86
Net Nonoperating Expense (NNE)		 8.04 8.25 8.21 6.50 8.33 1.53 4.65 6.48 3.99 2.69 12
Net Nonoperating Obligations (NNO)		 1.99 4.73 3.40 -5.18 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Total Depreciation and Amortization (D&A)		 2.07 2.14 2.86 2.58 1.45 0.95 0.97 1.01 0.82 0.76 0.44
Debt-free, Cash-free Net Working Capital to Revenue		 -31.67% -0.75% -5.62% 0.00% 0.00% 0.00% 0.00% -2,922.77% -111.36% -182.11% -182.39%
Debt-free Net Working Capital to Revenue		 264.70% 276.52% 374.64% 0.00% 0.00% 0.00% 0.00% 5,166.52% 62.75% -120.19% 69.17%
Net Working Capital to Revenue		 264.70% 134.15% -132.02% 0.00% 0.00% 0.00% 0.00% 4,448.66% -18.18% -176.72% 54.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($48.75) ($7.25)
Adjusted Weighted Average Basic Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 265.61K 3.11M
Adjusted Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($58.50) ($7.25)
Adjusted Weighted Average Diluted Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 308.03K 3.11M
Adjusted Basic & Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.25K 2.31K 4.32K 11.59K 92.27K 295.19K 805.95K 2.34M 4.28M 679.99K 6.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.70 -14 -9.32 -10 -11
Normalized NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Pre Tax Income Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.79% -271.04% -222.84% -429.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.15 -7.51 -10.09 -3.40 -1.97 -6.49 -13.40 -27.72 -33.72 -73.03 -40.06
NOPAT to Interest Expense		 -2.94 -5.32 -7.07 -3.19 -1.38 -6.06 -9.38 -19.41 -23.61 -57.47 -19.54
EBIT Less CapEx to Interest Expense		 -4.32 -7.49 -10.76 -3.47 -2.01 -6.57 -13.49 -28.44 -34.13 -73.84 -40.13
NOPAT Less CapEx to Interest Expense		 -3.11 -5.30 -7.74 -3.26 -1.42 -6.14 -9.47 -20.12 -24.01 -58.28 -19.61
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.04% -9.45% -9.16% 0.00% 0.00% 0.00% 0.00% -3.81% -3.56% -2.88% -1.03%

Quarterly Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,879,620.00 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 5,896,333.00 16,999,626.00 32,717,054.00 99,264,526.00 137,429,055.00 171,550,698.00
DEI Adjusted Shares Outstanding		 2,879,620.00 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 235,853.00 679,985.00 32,717,054.00 99,264,526.00 5,497,162.00 6,862,028.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.12 -0.84 -0.76 -0.69 -0.49 -16.55 -25.59 0.16 -0.04 -1.04 -1.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,598.63% 769.54% 231.42% -31.01% 17.42% 7.54% -36.85% 8.68% -4.05% -3.19% -2.93%
EBITDA Growth		 37.26% 30.30% 30.48% -131.97% 9.30% 3.99% -433.19% 283.00% -60.60% -54.64% 57.83%
EBIT Growth		 36.18% 30.76% 30.14% -100.00% 11.01% -1.09% -410.88% 271.95% -54.93% -47.23% 57.76%
NOPAT Growth		 36.18% 30.76% 30.14% -148.12% -16.86% -1.09% -7.18% 40.57% -17.98% -47.23% -101.33%
Net Income Growth		 38.32% 32.66% 32.13% -98.38% 10.72% -2.44% -433.61% 275.20% -53.90% -46.37% 60.08%
EPS Growth		 64.91% 62.54% 63.77% -20.34% 63.00% 51.24% -433.61% 98.59% 89.19% 261.02% 60.08%
Operating Cash Flow Growth		 43.18% 15.80% 22.10% 58.60% -53.40% 35.62% -36.76% -404.17% 30.76% -416.68% -1.07%
Free Cash Flow Firm Growth		 -618.72% -313.74% -300.08% 6,761.96% 98.17% 119.87% 1,039.14% -257.16% 6,975.89% -909.62% -235.55%
Invested Capital Growth		 -28.29% 5.65% 10.40% -262.32% -65.26% -56.31% -649.45% 69.89% -73.12% 9.66% 92.58%
Revenue Q/Q Growth		 -33.12% 5.89% 27.72% -23.73% 13.84% -3.02% -25.00% 31.26% 0.50% -2.15% -24.80%
EBITDA Q/Q Growth		 -147.70% -24.52% 16.90% 9.50% 3.14% -31.81% -361.47% 131.00% -185.00% -26.92% -25.85%
EBIT Q/Q Growth		 -118.19% -18.67% 14.49% 9.67% 2.92% -34.81% -332.15% 130.40% -187.47% -28.11% -23.98%
NOPAT Q/Q Growth		 -118.19% -18.67% 14.49% -12.06% -2.76% -2.66% 9.33% 37.86% -103.99% -28.11% -23.98%
Net Income Q/Q Growth		 -117.21% -18.36% 14.41% 9.84% 2.24% -35.80% -345.84% 129.60% -185.87% -29.17% -21.58%
EPS Q/Q Growth		 -69.49% -21.00% 38.02% 5.33% 47.89% -59.46% -345.84% 99.16% -300.00% 2,475.00% -21.58%
Operating Cash Flow Q/Q Growth		 13.64% 21.59% -139.93% 74.52% -220.00% 67.09% -409.66% 6.06% 56.05% -145.57% 0.30%
Free Cash Flow Firm Q/Q Growth		 -1,528.56% -120.51% 7.44% 335.34% -100.38% 2,499.21% 4,275.91% -139.38% 116.63% -382.50% -632.65%
Invested Capital Q/Q Growth		 -14.53% -46.83% 24.55% -185.57% 47.76% -38.88% -261.74% 88.53% -200.31% 27.53% 70.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -243.71% -286.60% -186.46% -221.27% -188.26% -255.88% -1,574.41% 372.59% -315.10% -408.71% -683.95%
Operating Margin		 -262.18% -293.83% -196.72% -289.05% -260.92% -276.20% -333.90% -110.65% -320.83% -420.04% -692.51%
EBIT Margin		 -262.18% -293.83% -196.72% -232.99% -198.70% -276.20% -1,591.50% 368.63% -320.83% -420.04% -692.51%
Profit (Net Income) Margin		 -259.60% -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.02% 98.76% 98.85% 98.66% 99.34% 100.08% 103.25% 100.53% 98.68% 99.49% 97.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -216.23% -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -54.06% -81.89% -112.60% -101.03% -112.32% -178.53% -937.42% 181.80% -131.54% -190.76% -224.48%
Return on Assets (ROA)		 -53.53% -80.88% -111.30% -99.68% -111.58% -178.66% -967.84% 182.76% -129.81% -189.79% -219.03%
Return on Common Equity (ROCE)		 -216.23% -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30%
Return on Equity Simple (ROE_SIMPLE)		 -578.34% 0.00% 243.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.28 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.54 -3.14 -4.02 -4.98
NOPAT Margin		 -183.52% -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -110.65% -224.58% -294.03% -484.76%
Net Nonoperating Expense Percent (NNEP)		 -8.90% -12.82% -26.07% -6.22% -5.27% -47.96% -314.19% 111.28% -14.21% -26.72% -16.14%
Return On Investment Capital (ROIC_SIMPLE)		 - -102.76% 185.19% 59.73% 141.30% 48.26% 10.47% -50.69% -62.08% -84.69% -39.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 161.13% 181.04% 131.96% 172.24% 164.63% 221.39% 268.08% 121.01% 246.46% 304.90% 513.81%
R&D to Revenue		 201.05% 212.80% 164.76% 216.81% 196.29% 154.82% 165.82% 89.64% 174.37% 215.14% 278.70%
Operating Expenses to Revenue		 362.18% 393.83% 296.72% 389.05% 360.92% 376.20% 433.90% 210.65% 420.83% 520.04% 792.51%
Earnings before Interest and Taxes (EBIT)		 -3.25 -3.86 -3.30 -2.98 -2.89 -3.90 -17 5.12 -4.48 -5.74 -7.12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.02 -3.76 -3.13 -2.83 -2.74 -3.61 -17 5.18 -4.40 -5.59 -7.03
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.47 0.00 0.00 0.00 0.00 0.00 0.00 3.75 13.43 17.62 2.33
Price to Tangible Book Value (P/TBV)		 1.75 0.00 0.00 0.00 0.00 0.00 0.00 5.03 15.75 21.39 2.47
Price to Revenue (P/Rev)		 1.03 1.61 1.27 1.14 1.50 1.16 3.10 2.14 12.91 13.51 5.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.68 1.33 0.21 1.24 1.11 1.21 0.85 9.75 11.13 2.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.66 -2.95 -0.74 -0.43 -0.64 -0.37 0.00 0.00 0.00 0.19 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.51 -3.39 3.38 2.28 3.20 0.48 0.33 2.62 150.81 2.56 2.08
Leverage Ratio		 2.59 6.92 -9.84 -5.12 -7.94 -1.75 -0.62 -4.70 -213.73 -4.64 -2.74
Compound Leverage Factor		 2.57 6.83 -9.72 -5.05 -7.89 -1.75 -0.64 -4.72 -210.92 -4.61 -2.67
Debt to Total Capital		 62.38% 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28%
Short-Term Debt to Total Capital		 62.38% 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 37.62% -51.29% 387.89% 175.98% 274.92% 158.19% 100.00% 100.00% 100.00% 84.20% 94.72%
Debt to EBITDA		 -0.31 -0.32 -0.32 -0.24 -0.23 -0.27 0.00 0.00 0.00 -0.03 -0.06
Net Debt to EBITDA		 0.47 0.37 -0.03 0.38 0.11 0.03 0.00 0.00 0.00 0.57 1.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.41 -0.43 -0.43 -0.33 -0.32 -0.32 0.00 0.00 0.00 -0.07 -0.05
Net Debt to NOPAT		 0.63 0.49 -0.04 0.52 0.15 0.03 0.00 0.00 0.00 1.15 1.09
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -50.47 -59.48 -122.22 -61.97 -99.51 -106.82 -63.21 -65.11 -35.52 -41.44 -34.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.10 0.92 0.41 0.50 0.44 0.34 1.03 1.26 1.29 1.23 2.27
Quick Ratio		 1.04 0.80 0.31 0.45 0.40 0.23 0.93 0.94 1.22 0.70 1.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.39 -3.06 -2.83 6.66 -0.03 0.61 27 -10 1.74 -4.91 -36
Operating Cash Flow to CapEx		 -23,990.00% -4,478.57% -11,282.50% -1,419.75% -26,285.71% -11,009.09% 0.00% -82,828.57% -9,437.04% -20,856.67% -762.59%
Free Cash Flow to Firm to Interest Expense		 -15.93 -49.28 -83.19 246.52 -0.41 10.65 48.47 0.00 0.00 0.00 -2,117.96
Operating Cash Flow to Interest Expense		 -27.57 -30.34 -132.74 -42.59 -60.33 -21.25 -11.26 0.00 0.00 0.00 -366.94
Operating Cash Flow Less CapEx to Interest Expense		 -27.69 -31.02 -133.91 -45.59 -60.56 -21.44 -11.21 0.00 0.00 0.00 -415.06
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.21 0.28 0.57 0.43 0.57 0.65 0.59 0.49 0.41 0.45 0.32
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.05 4.41 5.86 5.88 7.16 8.60 9.26 10.42 12.17 14.79 7.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.04 -5.93 -4.47 -13 -6.67 -9.26 -34 -3.85 -12 -8.37 -2.49
Invested Capital Turnover		 -1.04 -0.80 -1.29 -0.68 -1.07 -0.77 -0.27 -0.64 -0.58 -0.59 -0.29
Increase / (Decrease) in Invested Capital		 -0.89 0.36 0.52 -9.24 -2.63 -3.34 -29 8.92 -4.88 0.90 31
Enterprise Value (EV)		 -2.80 3.34 8.08 1.14 7.11 6.47 6.28 4.50 51 58 13
Market Capitalization		 3.86 7.92 7.72 6.29 8.61 6.78 16 11 68 70 28
Book Value per Share		 $0.91 ($0.30) ($1.13) ($1.17) ($0.88) ($1.52) ($4.01) $0.09 $0.05 $0.03 $0.07
Tangible Book Value per Share		 $0.76 ($0.39) ($1.23) ($1.32) ($1.03) ($1.66) ($4.15) $0.07 $0.04 $0.02 $0.07
Total Capital		 6.97 2.63 -1.25 -4.33 -1.88 -5.66 -24 3.03 5.05 4.75 13
Total Debt		 4.35 3.98 3.59 3.29 3.29 3.29 0.00 0.00 0.00 0.75 0.67
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -6.66 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14
Capital Expenditures (CapEx)		 0.01 0.04 0.04 0.08 0.01 0.01 -0.03 0.01 0.03 0.03 0.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.61 -5.47 -5.82 -15 -8.24 -11 -9.56 -4.98 -13 -9.51 -4.37
Debt-free Net Working Capital (DFNWC)		 5.39 3.08 -2.60 -6.12 -3.46 -7.00 0.31 1.90 3.97 3.61 11
Net Working Capital (NWC)		 1.05 -0.89 -6.19 -9.41 -6.75 -10 0.31 1.90 3.97 2.86 10
Net Nonoperating Expense (NNE)		 0.94 1.11 0.95 0.35 0.21 1.17 15 -6.69 1.29 1.69 1.96
Net Nonoperating Obligations (NNO)		 -6.66 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14
Total Depreciation and Amortization (D&A)		 0.23 0.10 0.17 0.15 0.15 0.29 0.18 0.06 0.08 0.16 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -149.61% -111.36% -95.66% -264.11% -144.00% -182.11% -183.60% -93.68% -240.22% -182.39% -84.41%
Debt-free Net Working Capital to Revenue		 143.80% 62.75% -42.67% -111.00% -60.37% -120.19% 5.94% 35.70% 75.50% 69.17% 207.26%
Net Working Capital to Revenue		 27.89% -18.18% -101.68% -170.76% -117.87% -176.72% 5.94% 35.70% 75.50% 54.79% 194.38%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.45) ($0.37) ($14.75) ($29.75) $0.02 ($0.04) $23.00 ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 3.23M 3.14M 4.32M 6.50M 7.86M 265.61K 582.67K 48.39M 107.43M 3.11M 6.65M
Adjusted Diluted Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.71) ($0.37) ($14.75) ($29.75) ($0.01) ($0.04) $23.75 ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 3.23M 3.14M 4.32M 10.74M 7.86M 308.03K 582.67K 209.15M 107.43M 3.11M 6.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.21) $0.00 $0.00 $0.00 ($14.75) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.52M 4.28M 0.00 5.90M 5.90M 679.99K 1.31M 99.26M 137.43M 6.86M 6.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.28 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.08 -3.14 -4.02 -4.98
Normalized NOPAT Margin		 -183.52% -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -77.45% -224.58% -294.03% -484.76%
Pre Tax Income Margin		 -259.60% -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -37.37 -62.23 -97.03 -110.37 -47.43 -68.42 -30.76 0.00 0.00 0.00 -418.76
NOPAT to Interest Expense		 -26.16 -43.56 -67.92 -95.85 -43.60 -47.89 -4.52 0.00 0.00 0.00 -293.14
EBIT Less CapEx to Interest Expense		 -37.48 -62.90 -98.21 -113.37 -47.66 -68.61 -30.71 0.00 0.00 0.00 -466.88
NOPAT Less CapEx to Interest Expense		 -26.27 -44.24 -69.10 -98.85 -43.82 -48.09 -4.47 0.00 0.00 0.00 -341.25
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.56% -7.20% -6.75% -6.58% -2.88% 0.00% -0.92% -1.12% -1.03% -13.36%

Financials Breakdown Chart

Key Financial Trends

Plus Therapeutics (NASDAQ: PSTV) remains a development-stage biotech with meaningful revenue fluctuations, persistent losses, and a balance sheet that has been heavily reshaped by financing activity over the past four years. The latest quarter, Q1 2026, showed revenue of $1.0 million but a net loss of $6.9 million, while cash declined by $5.7 million during the quarter.

From a retail investor perspective, the big picture is straightforward: PSTV is still spending far more than it brings in, and the company continues to rely on financing and investment activity to support operations. That said, it does still maintain a cash and short-term investment cushion, and quarterly revenue has been roughly stable in the $1 million to $1.4 million range recently.

  • Q1 2026 revenue was $1.03 million, up modestly from $1.37 million in Q4 2025 but slightly below recent quarterly levels from 2024 and 2025.
  • The company ended Q1 2026 with $15.1 million in cash and short-term investments, including $3.0 million in cash and $12.1 million in short-term investments.
  • Total current assets of $18.0 million exceeded total current liabilities of $8.0 million at the end of Q1 2026, suggesting a reasonable near-term liquidity position.
  • Operating cash burn improved versus the most recent prior quarter, with operating cash outflow narrowing to $6.2 million in Q1 2026 from $6.3 million in Q4 2025.
  • The company generated $2.0 million from sales/maturity of investments in Q1 2026, helping offset the cash burn.
  • R&D spending remains significant at $2.9 million in Q1 2026, reflecting continued investment in the pipeline.
  • SG&A expense was $5.3 million in Q1 2026, still a major component of the company’s cost structure.
  • The company’s quarterly net loss of $6.9 million was worse than the $5.7 million loss in Q4 2025, but better than the $17.4 million loss in Q1 2025, which included a large other expense item.
  • The share count has been highly volatile over the past year, making per-share comparisons less meaningful and suggesting substantial dilution activity.
  • PSTV has not yet demonstrated consistent profitability; it has posted losses in every reported quarter in this dataset except Q2 2025, when a large one-time gain pushed net income positive.
  • Operating income was negative $7.1 million in Q1 2026, showing that core operations remain unprofitable before interest and other items.
  • Cash and equivalents fell from $13.3 million at the end of Q3 2025 to $3.0 million by Q1 2026, indicating a sharp drop in liquid cash.
  • Total equity remains thin at $11.96 million in Q1 2026, after being negative in earlier periods, underscoring the company’s fragile capital structure.
  • The company relied on financing and other non-operating items to support liquidity, including $9.0 million of net financing cash inflow in Q1 2026.
  • In Q1 2025, the company reported a large accumulated deficit and negative equity position, highlighting how much capital has been consumed over time.

Bottom line: Plus Therapeutics has enough liquidity for now, but its financial model still depends on external funding and investment activity because operating losses remain substantial. Investors should watch cash runway, dilution risk, and whether revenue can begin to scale faster than expenses.

08/10/26 05:34 PM ETAI Generated. May Contain Errors.

Plus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Plus Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Plus Therapeutics' net income were at -$22.39 million at the end of 2025, a 72.5% increase from 2024, and a 19.4% increase since 2015. View Plus Therapeutics' forecast to see where analysts expect Plus Therapeutics to go next.

Plus Therapeutics' total operating income in 2025 was -$15.30 million, based on the following breakdown:
  • Total Gross Profit: $5.21 million
  • Total Operating Expenses: $20.51 million

Over the last 10 years, Plus Therapeutics' total revenue changed from $4.84 million in 2015 to $5.21 million in 2025, a change of 7.8%.

Plus Therapeutics' total liabilities were at $12.33 million at the end of 2025, a 20.9% decrease from 2024, and a 51.6% decrease since 2015.

In the past 10 years, Plus Therapeutics' cash and equivalents has ranged from $76 thousand in 2024 to $18.40 million in 2021, and is currently $4.26 million as of their latest financial filing in 2025.

Over the last 10 years, Plus Therapeutics' book value per share changed from 0.08 in 2015 to 0.03 in 2025, a change of -62.2%.


Related Companies

Financial statements for NASDAQ:PSTV last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Trump's Next Move Could Shrink Your Dollar
There's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...
Priority Gold | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel